Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 19/20 | 0.95 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.82 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.82 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.82 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.82 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.82 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.82 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.82 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.82 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.82 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.82 |
| ▸ | GHSR known ✓ | Q92847 | 1/20 | 0.82 |
| ▸ | IGF1R | P08069 | 1/20 | 0.95 |
| ▸ | MLNR | O43193 | 1/20 | 0.82 |
| ▸ | KDM1A | O60341 | 1/20 | 0.82 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.82 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.82 |
| ▸ | INSR | P06213 | 1/20 | 0.82 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.82 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29860673 | 0.97 | EGFR (1.00) | EGFRIGF1RMLNRKDM1AABCB11 | |
| SCHEMBL30379658 | 0.97 | EGFR (1.00) | EGFRIGF1RMLNRKDM1AABCB11 | |
| SCHEMBL14661086 | 0.97 | EGFR (1.00) | EGFRIGF1RMLNRKDM1AABCB11 | |
| Hydrochloric Acid SCHEMBL26637892 | 0.97 | EGFR (0.99) | EGFRIGF1RMLNRKDM1AABCB11 | |
| Hydrochloric Acid SCHEMBL30735819 | 0.97 | EGFR (0.99) | EGFRIGF1RMLNRKDM1AABCB11 | |
| Hydrochloric Acid SCHEMBL30735856 | 0.97 | EGFR (0.99) | EGFRIGF1RMLNRKDM1AABCB11 | |
| Osimertinib SCHEMBL29375936 | 0.93 | EGFR (0.95) | EGFRIGF1RMLNRKDM1AABCB11 | |
| Osimertinib SCHEMBL14661152 | 0.93 | EGFR (0.95) | EGFRIGF1RMLNRKDM1AABCB11 | |
| Osimertinib SCHEMBL29353024 | 0.93 | EGFR (0.95) | EGFRIGF1RMLNRKDM1AABCB11 | |
| SCHEMBL19337108 | 0.92 | EGFR (0.85) | EGFRIGF1RMLNRKDM1AABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| US-20240374610-A1 | METHOD AND PHARMACEUTICAL COMPOSITION FOR TREATING OR ALLEVIATING GLIOMAS IN A SUBJECT | ZHEJIANG UNIVERSITY (CN) | 2024-11-14 | — | — | US | claimed |
| US-20260000774-A1 | Insulin-Like Growth Factor Mimetic Peptide Modified Materials to Modify Cellular Inflammation | WASHINGTON UNIVERSITY (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | disclosed |
| US-20250275968-A1 | INHIBITORS OF TAU PROTEINS | DEUTSCHES ZENTRUM FÜR NEURODEGENERATIVE ERKRANKUNGEN E.V. (DE) | 2025-09-04 | — | — | US | disclosed |
| EP-4518858-A1 | INHIBITORS OF TAU PROTEINS | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DE) | 2025-03-12 | — | — | EP | disclosed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | disclosed |
| US-20240374610-A1 | METHOD AND PHARMACEUTICAL COMPOSITION FOR TREATING OR ALLEVIATING GLIOMAS IN A SUBJECT | ZHEJIANG UNIVERSITY (CN) | 2024-11-14 | — | — | US | disclosed |
| WO-2023243971-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DEMYELINATING DISEASE, COMPRISING KINASE INHIBITOR AS ACTIVE INGREDIENT | 고려대학교 산학협력단 | 2023-12-21 | — | — | WO | disclosed |
| WO-2023213850-A1 | INHIBITORS OF TAU PROTEINS | DEUTSCHES ZENTRUM FÜR NEURODEGENERATIVE ERKRANKUNGEN E. V. (DZNE) (DE) | 2023-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250275968-A1 | INHIBITORS OF TAU PROTEINS | MAPT, PSEN2, PSEN1 | EGFR 4305/4885HTR1A 3970/4885DRD2 4810/4885 |
| US-20260000774-A1 | Insulin-Like Growth Factor Mimetic Peptide Modified Materials to Modify Cellular Inflammation | IGFBP3, IGFBP1, IGF1R | EGFR 831/4885HTR1A 2240/4885DRD2 2954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.